An innovative fund combining resources from public, non-profit and for-profit organisations has set out to ease bottlenecks in late-stage research and development in global health while rewarding investors financially.
The Global Health Investment Fund launched on 23 September pools US$94 million from various funders including the Bill and Melinda Gates Foundation, aid agencies in Sweden and Canada, and private companies Pfizer, Merck and JP Morgan Chase.
“We are interested in late-stage clinical trial candidates focused on a global health disease; a disease which disproportionately affects patients in low-income countries,” says Julia Fan Li, GHIF director at Lions Head, the UK based investment bank that manages the fund.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.